Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Baird Initiates Coverage On Longboard Pharmaceuticals with Outperform Rating, Announces Price Target of $36

Author: Benzinga Newsdesk | May 01, 2024 05:23am
Baird analyst Joel Beatty initiates coverage on Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform rating and announces Price Target of $36.

Posted In: LBPH

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist